Name: Partnering for innovative stroke treatments: Interview with Liz Dallimore, CEO of Argenica Therapeutics
Uploaded: 2023-08-07T05:14:55.582Z
Duration: 348.93

Edited Video 1st Inteview BRETT.mp4

Edited Video 1st Inteview BRETT.vtt

Subtitles

{{00:00:06}}
We did go through a pretty

{{00:00:07}}
extensive due diligence

{{00:00:08}}
process, so we looked

{{00:00:10}}
sort of globally and

{{00:00:13}}
then sort of brought it

{{00:00:13}}
back down into Australia.

{{00:00:24}}
I have, Liz Dallimore,

{{00:00:26}}
who's the CEO of Argenica

{{00:00:27}}
Therapeutics, and welcome Liz.

{{00:00:29}}
Thanks Tina.

{{00:00:30}}
And I want to just have a

{{00:00:32}}
quick snapshot of, working

{{00:00:35}}
with you as a client,

{{00:00:36}}
which we're delighted to

{{00:00:37}}
do so, and we, we are very

{{00:00:38}}
innovative company based in

{{00:00:40}}
Perth, looking at innovative

{{00:00:42}}
treatments for acute stroke.

{{00:00:43}}
Yeah.

{{00:00:44}}
And what I'd like to know and,

{{00:00:46}}
and understand, especially

{{00:00:47}}
for our audience, if that's

{{00:00:48}}
okay, is when you were looking

{{00:00:51}}
for a partner, a CRO, What

{{00:00:53}}
was important to you and

{{00:00:55}}
ultimately in selecting Lithia

{{00:00:57}}
to support your project?

{{00:00:58}}
Yeah, sure.

{{00:00:59}}
So we did go through

{{00:01:00}}
a pretty extensive due

{{00:01:02}}
diligence process so we

{{00:01:04}}
looked sort of, globally

{{00:01:06}}
and then sort of brought it

{{00:01:08}}
back down into Australia.

{{00:01:09}}
So I guess for us, the key,

{{00:01:11}}
number one priority was,

{{00:01:14}}
really someone that had had.

{{00:01:15}}
The experience in stroke.

{{00:01:17}}
So we are running a acute

{{00:01:19}}
trial in emergency department,

{{00:01:21}}
so it's, it's pretty full on.

{{00:01:23}}
So, you know, I, I knew

{{00:01:24}}
you and I knew that you

{{00:01:25}}
had done that work, so,

{{00:01:26}}
that was really important.

{{00:01:28}}
But people that we get on

{{00:01:29}}
with Tina, So you know that

{{00:01:32}}
we can pick up the phone.

{{00:01:33}}
They know, you know, you

{{00:01:34}}
know what we're do can do.

{{00:01:36}}
Attitude.

{{00:01:37}}
Yes.

{{00:01:37}}
Yes, exactly.

{{00:01:37}}
Culturally and team.

{{00:01:39}}
Yeah.

{{00:01:39}}
But also getting on with

{{00:01:40}}
things that, you know,

{{00:01:41}}
that just need to be done.

{{00:01:42}}
So that's really important.

{{00:01:43}}
So you don't, you know, have

{{00:01:44}}
a million phone calls asking

{{00:01:45}}
if you can do certain things.

{{00:01:46}}
You just.

{{00:01:47}}
Your team just gets on and do,

{{00:01:49}}
does it, which is fantastic.

{{00:01:50}}
Yeah.

{{00:01:50}}
Fantastic.

{{00:01:51}}
And what do you think,

{{00:01:52}}
so it's not necessarily

{{00:01:54}}
about the, the cost, but

{{00:01:55}}
it's about the experience

{{00:01:56}}
and I guess the cultural

{{00:01:58}}
fit with, with finding the

{{00:01:59}}
right partner to do that.

{{00:02:00}}
Yeah, absolutely.

{{00:02:02}}
Yeah.

{{00:02:02}}
As well.

{{00:02:02}}
And I guess our role

{{00:02:04}}
with Argenica has,

{{00:02:06}}
been to helping you.

{{00:02:08}}
As your project lead,

{{00:02:09}}
because you are like many

{{00:02:11}}
biotech companies, you have a

{{00:02:12}}
smaller almost virtual team.

{{00:02:15}}
Yes.

{{00:02:15}}
So I guess it is important

{{00:02:16}}
to have a project lead.

{{00:02:19}}
So one of the things

{{00:02:19}}
that we did for you was

{{00:02:20}}
helping you find a CRO that

{{00:02:23}}
could, a larger CRO with

{{00:02:25}}
a, global presence Yeah.

{{00:02:27}}
As well.

{{00:02:27}}
So, Did you want to talk about

{{00:02:31}}
some of the aspects that,

{{00:02:33}}
how important that is to you?

{{00:02:34}}
Yeah.

{{00:02:34}}
And what we were

{{00:02:34}}
helped you Yeah.

{{00:02:36}}
Helped your team member.

{{00:02:37}}
Sure.

{{00:02:37}}
You know?

{{00:02:37}}
Sure.

{{00:02:38}}
I think, I think for us,

{{00:02:38}}
the, you know, to date, you

{{00:02:41}}
know, given that the trial

{{00:02:42}}
hasn't started yet, but the,

{{00:02:43}}
the most value that I guess

{{00:02:44}}
we've extracted from you

{{00:02:45}}
and your team is just going

{{00:02:48}}
through the nitty gritty of

{{00:02:49}}
working with a global CROs.

{{00:02:52}}
So, you know, understanding

{{00:02:53}}
what's needed and,

{{00:02:55}}
and what's not needed.

{{00:02:56}}
So there's probably a lot of

{{00:02:57}}
padding in those scopes of

{{00:03:01}}
work with those global CROs.

{{00:03:03}}
So really working

{{00:03:04}}
through almost line by

{{00:03:06}}
line, even the cost.

{{00:03:07}}
You know, I think you've

{{00:03:07}}
already saved us considerable

{{00:03:10}}
amount of money on that

{{00:03:11}}
sort of, that first

{{00:03:12}}
cut of the CRO costs.

{{00:03:14}}
So, and then working

{{00:03:15}}
out, I think, you know,

{{00:03:17}}
what we sort of, worked

{{00:03:18}}
out pretty quickly was.

{{00:03:20}}
You know, having sort of

{{00:03:21}}
that management of the

{{00:03:22}}
DSMB, you know, by global

{{00:03:25}}
CRO probably wasn't gonna

{{00:03:26}}
be the best fit for us.

{{00:03:27}}
So we really did want that,

{{00:03:29}}
that local presence and,

{{00:03:30}}
and a bit more hands on.

{{00:03:31}}
So understanding what

{{00:03:32}}
we could take away from

{{00:03:33}}
the global CRO and.

{{00:03:35}}
Bring into Lithia and

{{00:03:36}}
also into our team was,

{{00:03:38}}
was really helpful.

{{00:03:38}}
Yes.

{{00:03:38}}
And I, and I would agree

{{00:03:39}}
because this is our bread

{{00:03:40}}
and butter so we understand

{{00:03:43}}
and we can, I guess, could

{{00:03:44}}
compare apples with apples.

{{00:03:46}}
We were looking at different

{{00:03:47}}
CROs and, and whilst they

{{00:03:49}}
provided everything, 'cause

{{00:03:50}}
I think that was the brief,

{{00:03:51}}
to be fair to them, we

{{00:03:52}}
were able then to put them

{{00:03:54}}
alongside each other, the

{{00:03:55}}
different assumptions or the

{{00:03:56}}
costs, and then take out what

{{00:03:58}}
we didn't need as a team.

{{00:04:00}}
Yeah.

{{00:04:00}}
And when I say us, I

{{00:04:01}}
mean our jenica and

{{00:04:03}}
Lithia working together.

{{00:04:04}}
Yeah.

{{00:04:04}}
So I think that's, Where

{{00:04:05}}
our agility and depth of

{{00:04:07}}
expertise comes, comes into

{{00:04:08}}
it and then taking even some

{{00:04:10}}
parts and doing them more,

{{00:04:12}}
cost effectively, I guess,

{{00:04:14}}
and more locally, where it's

{{00:04:16}}
important to claim the RAD

{{00:04:18}}
tax incentive, for example.

{{00:04:19}}
So we were able to make

{{00:04:21}}
it a good fit for the

{{00:04:22}}
client of as to what the

{{00:04:23}}
client needs, which will be

{{00:04:24}}
different for every client.

{{00:04:26}}
Yeah.

{{00:04:26}}
So, yeah, I think for

{{00:04:27}}
us, you know, the other

{{00:04:29}}
really important thing was

{{00:04:30}}
relationships with, the PIS.

{{00:04:33}}
Yeah.

{{00:04:33}}
And the actual, so, so for

{{00:04:35}}
us, the, the recruitment

{{00:04:36}}
time is absolutely critical.

{{00:04:38}}
We're a listed company

{{00:04:39}}
and everyone wants,

{{00:04:40}}
timelines to be met.

{{00:04:42}}
And, and recruitment really

{{00:04:43}}
is gonna be the thing that

{{00:04:44}}
kind of makes it or breaks it.

{{00:04:45}}
So having those relationships

{{00:04:47}}
with the, the principal

{{00:04:48}}
in Western, which we had

{{00:04:49}}
already at site, which

{{00:04:51}}
you, you already had, so

{{00:04:52}}
you're very well known.

{{00:04:53}}
So, Again, another for us,

{{00:04:55}}
another really important

{{00:04:56}}
sort of factor in, in

{{00:04:58}}
bringing you on board.

{{00:04:58}}
And I think half of the

{{00:04:59}}
battle when you are in

{{00:05:00}}
that startup phase in

{{00:05:01}}
clinical trials is not only

{{00:05:03}}
understanding the system

{{00:05:04}}
and the depth of what you

{{00:05:06}}
are, what you need as well.

{{00:05:08}}
You don't know what you

{{00:05:08}}
don't know and using experts

{{00:05:11}}
in that field, but also

{{00:05:12}}
that depth of relationship

{{00:05:13}}
where you've already got

{{00:05:15}}
the trust and rapport.

{{00:05:16}}
With, with these

{{00:05:17}}
clinicians, and in this

{{00:05:18}}
case it was stroke.

{{00:05:19}}
But of course we have

{{00:05:20}}
very, you know, depth of

{{00:05:21}}
knowledge in a lot of rare,

{{00:05:24}}
pediatric neurological

{{00:05:25}}
disorders as well.

{{00:05:26}}
Yeah.

{{00:05:26}}
So we were able to pivot

{{00:05:28}}
that for our client and

{{00:05:29}}
just get on with it.

{{00:05:29}}
Yeah, yeah, yeah.

{{00:05:30}}
And not, and, and not

{{00:05:31}}
use up that valuable time

{{00:05:32}}
and, You were then able

{{00:05:33}}
to report back to market

{{00:05:35}}
about the achievements.

{{00:05:36}}
Exactly.

{{00:05:36}}
You know, and we're

{{00:05:37}}
already in ethics and

{{00:05:38}}
so it's been wonderful.

{{00:05:39}}
Yes.

{{00:05:39}}
So thank you, Liz.

{{00:05:41}}
No problem.

{{00:05:41}}
Thanks.

Expert Insight

In this insightful interview, A/Prof Tina Soulis sit down with Liz Dallimore, the visionary CEO of Argenica Therapeutics, a cutting-edge biotech company based in Perth.

Discover how Liz and her team navigated the complexities of working with a global CRO and found tailored solutions to optimize their research process. 

Don't miss this opportunity to gain firsthand knowledge from a trailblazing leader in the biotech industry.


Bio Connections

thumbnail_Tina-Soulis1.jpg

xsmall_Tina-Soulis1.jpg

Tina-Soulis1.jpg

Tina Soulis

Founder & Director

thumbnail_1656301545382.jpg

xsmall_1656301545382.jpg

1656301545382.jpg

Dr Liz Dallimore

CEO & Managing Director

 Partner selection criteria

The crucial role of partnerships

medium_Bio Connection (8).png

small_Bio Connection (8).png

thumbnail_Bio Connection (8).png

xsmall_Bio Connection (8).png

Bio Connection (8).png

Partnering for innovative stroke treatments: Interview with Liz Dallimore, CEO of Argenica Therapeutics

Funding, Policy & Reform